Global and China Neuroendocrine Tumor Drug Market Insights, Forecast to 2026

Global and China Neuroendocrine Tumor Drug Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Neuroendocrine Tumor Drug Product Introduction
1.2 Market Segments
1.3 Key Neuroendocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type
1.4.2 mTOR protein inhibitors
1.4.3 Tyrosine kinase 3 inhibitors
1.4.4 Somatostatin receptor antagonists
1.4.5 Growth hormone releasing factor antagonists
1.4.6 Somatostatin receptor agonists
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Tumor Drug Market Size, Estimates and Forecasts
2.1.1 Global Neuroendocrine Tumor Drug Revenue 2015-2026
2.1.2 Global Neuroendocrine Tumor Drug Sales 2015-2026
2.2 Global Neuroendocrine Tumor Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Neuroendocrine Tumor Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Neuroendocrine Tumor Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Neuroendocrine Tumor Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Region (2021-2026)
3 Global Neuroendocrine Tumor Drug Competitor Landscape by Players
3.1 Global Top Neuroendocrine Tumor Drug Sales by Manufacturers
3.1.1 Global Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Neuroendocrine Tumor Drug Manufacturers by Revenue
3.2.1 Global Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2019
3.2.5 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Neuroendocrine Tumor Drug Price by Manufacturers
3.4 Global Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2015-2020)
4.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020)
4.1.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2021-2026)
4.2.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuroendocrine Tumor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2015-2020)
5.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2015-2020)
5.1.3 Neuroendocrine Tumor Drug Price by Application (2015-2020)
5.2 Neuroendocrine Tumor Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Tumor Drug Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
6.1.1 China Neuroendocrine Tumor Drug Sales YoY Growth 2015-2026
6.1.2 China Neuroendocrine Tumor Drug Revenue YoY Growth 2015-2026
6.1.3 China Neuroendocrine Tumor Drug Market Share in Global Market 2015-2026
6.2 China Neuroendocrine Tumor Drug Market Size by Players (International and Local Players)
6.2.1 China Top Neuroendocrine Tumor Drug Players by Sales (2015-2020)
6.2.2 China Top Neuroendocrine Tumor Drug Players by Revenue (2015-2020)
6.3 China Neuroendocrine Tumor Drug Historic Market Review by Type (2015-2020)
6.3.1 China Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
6.3.2 China Neuroendocrine Tumor Drug Revenue Market Share by Type (2015-2020)
6.3.3 China Neuroendocrine Tumor Drug Price by Type (2015-2020)
6.4 China Neuroendocrine Tumor Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2026)
6.4.2 China Neuroendocrine Tumor Drug Revenue Forecast by Type (2021-2026)
6.4.3 China Neuroendocrine Tumor Drug Price Forecast by Type (2021-2026)
6.5 China Neuroendocrine Tumor Drug Historic Market Review by Application (2015-2020)
6.5.1 China Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
6.5.2 China Neuroendocrine Tumor Drug Revenue Market Share by Application (2015-2020)
6.5.3 China Neuroendocrine Tumor Drug Price by Application (2015-2020)
6.6 China Neuroendocrine Tumor Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2026)
6.6.2 China Neuroendocrine Tumor Drug Revenue Forecast by Application (2021-2026)
6.6.3 China Neuroendocrine Tumor Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
7.2 North America Neuroendocrine Tumor Drug Market Facts & Figures by Country
7.2.1 North America Neuroendocrine Tumor Drug Sales by Country (2015-2020)
7.2.2 North America Neuroendocrine Tumor Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
8.2 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Country
8.2.1 Europe Neuroendocrine Tumor Drug Sales by Country
8.2.2 Europe Neuroendocrine Tumor Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
10.2 Latin America Neuroendocrine Tumor Drug Market Facts & Figures by Country
10.2.1 Latin America Neuroendocrine Tumor Drug Sales by Country
10.2.2 Latin America Neuroendocrine Tumor Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
11.2.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Eisai
12.1.1 Eisai Corporation Information
12.1.2 Eisai Description and Business Overview
12.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
12.1.5 Eisai Recent Development
12.2 Exelixis, Inc.
12.2.1 Exelixis, Inc. Corporation Information
12.2.2 Exelixis, Inc. Description and Business Overview
12.2.3 Exelixis, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
12.2.5 Exelixis, Inc. Recent Development
12.3 Foresee Pharmaceuticals, LLC
12.3.1 Foresee Pharmaceuticals, LLC Corporation Information
12.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
12.3.3 Foresee Pharmaceuticals, LLC Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
12.3.5 Foresee Pharmaceuticals, LLC Recent Development
12.4 Hutchison MediPharma Limited
12.4.1 Hutchison MediPharma Limited Corporation Information
12.4.2 Hutchison MediPharma Limited Description and Business Overview
12.4.3 Hutchison MediPharma Limited Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
12.4.5 Hutchison MediPharma Limited Recent Development
12.5 Intezyne, Inc
12.5.1 Intezyne, Inc Corporation Information
12.5.2 Intezyne, Inc Description and Business Overview
12.5.3 Intezyne, Inc Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
12.5.5 Intezyne, Inc Recent Development
12.6 INVENT Pharmaceuticals, Inc.
12.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
12.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
12.6.3 INVENT Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
12.6.5 INVENT Pharmaceuticals, Inc. Recent Development
12.7 Ipsen S.A.
12.7.1 Ipsen S.A. Corporation Information
12.7.2 Ipsen S.A. Description and Business Overview
12.7.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
12.7.5 Ipsen S.A. Recent Development
12.8 Jiangsu Hengrui Medicine Co., Ltd.
12.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
12.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
12.8.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
12.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
12.9 Karyopharm Therapeutics, Inc.
12.9.1 Karyopharm Therapeutics, Inc. Corporation Information
12.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
12.9.3 Karyopharm Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
12.9.5 Karyopharm Therapeutics, Inc. Recent Development
12.10 Lexicon Pharmaceuticals, Inc.
12.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
12.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
12.10.3 Lexicon Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
12.10.5 Lexicon Pharmaceuticals, Inc. Recent Development
12.11 Eisai
12.11.1 Eisai Corporation Information
12.11.2 Eisai Description and Business Overview
12.11.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Eisai Neuroendocrine Tumor Drug Products Offered
12.11.5 Eisai Recent Development
12.12 Millennium Pharmaceuticals, Inc.
12.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
12.12.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
12.12.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Millennium Pharmaceuticals, Inc. Products Offered
12.12.5 Millennium Pharmaceuticals, Inc. Recent Development
12.13 MolMed S.p.A.
12.13.1 MolMed S.p.A. Corporation Information
12.13.2 MolMed S.p.A. Description and Business Overview
12.13.3 MolMed S.p.A. Sales, Revenue and Gross Margin (2015-2020)
12.13.4 MolMed S.p.A. Products Offered
12.13.5 MolMed S.p.A. Recent Development
12.14 Northwest Biotherapeutics, Inc.
12.14.1 Northwest Biotherapeutics, Inc. Corporation Information
12.14.2 Northwest Biotherapeutics, Inc. Description and Business Overview
12.14.3 Northwest Biotherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Northwest Biotherapeutics, Inc. Products Offered
12.14.5 Northwest Biotherapeutics, Inc. Recent Development
12.15 Novartis AG
12.15.1 Novartis AG Corporation Information
12.15.2 Novartis AG Description and Business Overview
12.15.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Novartis AG Products Offered
12.15.5 Novartis AG Recent Development
12.16 OctreoPharm Sciences GmbH
12.16.1 OctreoPharm Sciences GmbH Corporation Information
12.16.2 OctreoPharm Sciences GmbH Description and Business Overview
12.16.3 OctreoPharm Sciences GmbH Sales, Revenue and Gross Margin (2015-2020)
12.16.4 OctreoPharm Sciences GmbH Products Offered
12.16.5 OctreoPharm Sciences GmbH Recent Development
12.17 OXiGENE, Inc.
12.17.1 OXiGENE, Inc. Corporation Information
12.17.2 OXiGENE, Inc. Description and Business Overview
12.17.3 OXiGENE, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.17.4 OXiGENE, Inc. Products Offered
12.17.5 OXiGENE, Inc. Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Neuroendocrine Tumor Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Tumor Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Neuroendocrine Tumor Drug Market Segments
Table 2. Ranking of Global Top Neuroendocrine Tumor Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of mTOR protein inhibitors
Table 5. Major Manufacturers of Tyrosine kinase 3 inhibitors
Table 6. Major Manufacturers of Somatostatin receptor antagonists
Table 7. Major Manufacturers of Growth hormone releasing factor antagonists
Table 8. Major Manufacturers of Somatostatin receptor agonists
Table 9. Major Manufacturers of Others
Table 10. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Neuroendocrine Tumor Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Neuroendocrine Tumor Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Neuroendocrine Tumor Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Neuroendocrine Tumor Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 16. Global Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 17. Global Neuroendocrine Tumor Drug Sales Share by Manufacturers (2015-2020)
Table 18. Global Neuroendocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Drug as of 2019)
Table 20. Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Neuroendocrine Tumor Drug Price (2015-2020) (USD/Pcs)
Table 23. Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Neuroendocrine Tumor Drug Product Type
Table 25. Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 28. Global Neuroendocrine Tumor Drug Sales Share by Type (2015-2020)
Table 29. Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Neuroendocrine Tumor Drug Revenue Share by Type (2015-2020)
Table 31. Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 32. Global Neuroendocrine Tumor Drug Sales Share by Type (2021-2026)
Table 33. Global Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 34. Global Neuroendocrine Tumor Drug Sales Share by Application (2015-2020)
Table 35. Global Neuroendocrine Tumor Drug Sales Share by Application (2021-2026)
Table 36. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Application (2021-2026)
Table 37. Global Neuroendocrine Tumor Drug Revenue by Application (2015-2020) (US$ Million)
Table 38. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Application (2021-2026)
Table 39. China Neuroendocrine Tumor Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 40. China Neuroendocrine Tumor Drug Sales Share by Company (2015-2020)
Table 41. China Neuroendocrine Tumor Drug Revenue (US$ Million) by Company (2015-2020)
Table 42. China Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2015-2020)
Table 43. China Neuroendocrine Tumor Drug Sales Share by Type (2015-2020)
Table 44. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 45. China Neuroendocrine Tumor Drug Price (K Pcs) by Type (2015-2020)
Table 46. China Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2021-2026)
Table 47. China Neuroendocrine Tumor Drug Sales Share by Type (2021-2026)
Table 48. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 49. China Neuroendocrine Tumor Drug Revenue Share by Type (2021-2026)
Table 50. China Neuroendocrine Tumor Drug Price (K Pcs) by Type (2021-2026)
Table 51. China Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2015-2020)
Table 52. China Neuroendocrine Tumor Drug Sales Share by Application (2015-2020)
Table 53. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 54. China Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2021-2026)
Table 55. China Neuroendocrine Tumor Drug Sales Share by Application (2021-2026)
Table 56. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 57. China Neuroendocrine Tumor Drug Revenue Share by Application (2021-2026)
Table 58. North America Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 59. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 60. North America Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 61. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 62. Europe Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 63. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 64. Europe Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 66. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2015-2020) (K Pcs)
Table 67. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2015-2020)
Table 68. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2015-2020) (US$ Million)
Table 69. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2015-2020)
Table 70. Latin America Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 71. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 72. Latin Americaa Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 73. Latin America Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 74. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 75. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 76. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 77. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 78. Eisai Corporation Information
Table 79. Eisai Description and Business Overview
Table 80. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Eisai Neuroendocrine Tumor Drug Product
Table 82. Eisai Recent Development
Table 83. Exelixis, Inc. Corporation Information
Table 84. Exelixis, Inc. Description and Business Overview
Table 85. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Exelixis, Inc. Product
Table 87. Exelixis, Inc. Recent Development
Table 88. Foresee Pharmaceuticals, LLC Corporation Information
Table 89. Foresee Pharmaceuticals, LLC Description and Business Overview
Table 90. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Foresee Pharmaceuticals, LLC Product
Table 92. Foresee Pharmaceuticals, LLC Recent Development
Table 93. Hutchison MediPharma Limited Corporation Information
Table 94. Hutchison MediPharma Limited Description and Business Overview
Table 95. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Hutchison MediPharma Limited Product
Table 97. Hutchison MediPharma Limited Recent Development
Table 98. Intezyne, Inc Corporation Information
Table 99. Intezyne, Inc Description and Business Overview
Table 100. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Intezyne, Inc Product
Table 102. Intezyne, Inc Recent Development
Table 103. INVENT Pharmaceuticals, Inc. Corporation Information
Table 104. INVENT Pharmaceuticals, Inc. Description and Business Overview
Table 105. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. INVENT Pharmaceuticals, Inc. Product
Table 107. INVENT Pharmaceuticals, Inc. Recent Development
Table 108. Ipsen S.A. Corporation Information
Table 109. Ipsen S.A. Description and Business Overview
Table 110. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Ipsen S.A. Product
Table 112. Ipsen S.A. Recent Development
Table 113. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 114. Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
Table 115. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Jiangsu Hengrui Medicine Co., Ltd. Product
Table 117. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 118. Karyopharm Therapeutics, Inc. Corporation Information
Table 119. Karyopharm Therapeutics, Inc. Description and Business Overview
Table 120. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Karyopharm Therapeutics, Inc. Product
Table 122. Karyopharm Therapeutics, Inc. Recent Development
Table 123. Lexicon Pharmaceuticals, Inc. Corporation Information
Table 124. Lexicon Pharmaceuticals, Inc. Description and Business Overview
Table 125. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Lexicon Pharmaceuticals, Inc. Product
Table 127. Lexicon Pharmaceuticals, Inc. Recent Development
Table 128. Midatech Pharma Plc . Corporation Information
Table 129. Midatech Pharma Plc . Description and Business Overview
Table 130. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Midatech Pharma Plc . Product
Table 132. Midatech Pharma Plc . Recent Development
Table 133. Millennium Pharmaceuticals, Inc. Corporation Information
Table 134. Millennium Pharmaceuticals, Inc. Description and Business Overview
Table 135. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Millennium Pharmaceuticals, Inc. Product
Table 137. Millennium Pharmaceuticals, Inc. Recent Development
Table 138. MolMed S.p.A. Corporation Information
Table 139. MolMed S.p.A. Description and Business Overview
Table 140. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. MolMed S.p.A. Product
Table 142. MolMed S.p.A. Recent Development
Table 143. Northwest Biotherapeutics, Inc. Corporation Information
Table 144. Northwest Biotherapeutics, Inc. Description and Business Overview
Table 145. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. Northwest Biotherapeutics, Inc. Product
Table 147. Northwest Biotherapeutics, Inc. Recent Development
Table 148. Novartis AG Corporation Information
Table 149. Novartis AG Description and Business Overview
Table 150. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. Novartis AG Product
Table 152. Novartis AG Recent Development
Table 153. OctreoPharm Sciences GmbH Corporation Information
Table 154. OctreoPharm Sciences GmbH Description and Business Overview
Table 155. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. OctreoPharm Sciences GmbH Product
Table 157. OctreoPharm Sciences GmbH Recent Development
Table 158. OXiGENE, Inc. Corporation Information
Table 159. OXiGENE, Inc. Description and Business Overview
Table 160. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 161. OXiGENE, Inc. Product
Table 162. OXiGENE, Inc. Recent Development
Table 163. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 164. Key Challenges
Table 165. Market Risks
Table 166. Main Points Interviewed from Key Neuroendocrine Tumor Drug Players
Table 167. Neuroendocrine Tumor Drug Customers List
Table 168. Neuroendocrine Tumor Drug Distributors List
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroendocrine Tumor Drug Product Picture
Figure 2. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2020 & 2026
Figure 3. mTOR protein inhibitors Product Picture
Figure 4. Tyrosine kinase 3 inhibitors Product Picture
Figure 5. Somatostatin receptor antagonists Product Picture
Figure 6. Growth hormone releasing factor antagonists Product Picture
Figure 7. Somatostatin receptor agonists Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Neuroendocrine Tumor Drug Report Years Considered
Figure 14. Global Neuroendocrine Tumor Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Neuroendocrine Tumor Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Neuroendocrine Tumor Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Neuroendocrine Tumor Drug Sales Market Share by Region in 2019
Figure 19. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Neuroendocrine Tumor Drug Revenue Market Share by Region in 2019
Figure 21. Global Neuroendocrine Tumor Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Neuroendocrine Tumor Drug Revenue in 2019
Figure 23. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2019
Figure 26. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Neuroendocrine Tumor Drug Revenue Market Share by Type in 2019
Figure 28. Global Neuroendocrine Tumor Drug Market Share by Price Range (2015-2020)
Figure 29. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2019
Figure 31. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2019
Figure 33. China Neuroendocrine Tumor Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 34. China Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 35. China Neuroendocrine Tumor Drug Market Share in Global Market 2015-2026
Figure 36. China 5 and 10 Largest Neuroendocrine Tumor Drug Players Market Share by Revenue in Neuroendocrine Tumor Drug in 2019
Figure 37. China Neuroendocrine Tumor Drug Revenue Share by Type (2015-2020)
Figure 38. China Neuroendocrine Tumor Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 39. China Neuroendocrine Tumor Drug Revenue Share by Application (2015-2020)
Figure 40. China Neuroendocrine Tumor Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 41. North America Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. North America Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. North America Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 44. North America Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 45. U.S. Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. U.S. Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Canada Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Canada Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Europe Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 50. Europe Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 51. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 52. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 53. Germany Neuroendocrine Tumor Dr

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global 5-Fluorouracil Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76

The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......

Global Carboplatin Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......

Global Neutropenia Drugs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96

The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......

Global Small Molecule Cancer Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......

Global Capecitabine Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80

Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......

Global Oxaliplatin Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......

Global Cancer Treatment Drugs Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158

According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......

Global Capecitabine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93

According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......

Global Methotrexate Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs